1. Home
  2. PRZO vs CMMB Comparison

PRZO vs CMMB Comparison

Compare PRZO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.57

Market Cap

12.0M

Sector

N/A

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.80

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
CMMB
Founded
2014
2004
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
10.5M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
PRZO
CMMB
Price
$0.57
$1.80
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
630.4K
142.0K
Earning Date
03-26-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$43.75
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.87
52 Week High
$1.90
$3.86

Technical Indicators

Market Signals
Indicator
PRZO
CMMB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
PRZO
CMMB

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: